WO2005046662A3 - Hdl-boosting combination therapy complexes - Google Patents

Hdl-boosting combination therapy complexes Download PDF

Info

Publication number
WO2005046662A3
WO2005046662A3 PCT/US2004/037324 US2004037324W WO2005046662A3 WO 2005046662 A3 WO2005046662 A3 WO 2005046662A3 US 2004037324 W US2004037324 W US 2004037324W WO 2005046662 A3 WO2005046662 A3 WO 2005046662A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdl
combination therapy
complexes
boosting
boosting combination
Prior art date
Application number
PCT/US2004/037324
Other languages
French (fr)
Other versions
WO2005046662A2 (en
Inventor
Josefino B Tunac
Original Assignee
Jj Pharma Inc
Josefino B Tunac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jj Pharma Inc, Josefino B Tunac filed Critical Jj Pharma Inc
Priority to EP04810579A priority Critical patent/EP1680099B1/en
Priority to AT04810579T priority patent/ATE428411T1/en
Priority to JP2006538551A priority patent/JP4839221B2/en
Priority to CA002543596A priority patent/CA2543596A1/en
Priority to DE602004020649T priority patent/DE602004020649D1/en
Publication of WO2005046662A2 publication Critical patent/WO2005046662A2/en
Publication of WO2005046662A3 publication Critical patent/WO2005046662A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inhibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent.
PCT/US2004/037324 2003-11-07 2004-11-08 Hdl-boosting combination therapy complexes WO2005046662A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04810579A EP1680099B1 (en) 2003-11-07 2004-11-08 Hdl-boosting combination therapy complexes
AT04810579T ATE428411T1 (en) 2003-11-07 2004-11-08 HDL-BOOSTING COMBINATION THERAPY COMPLEXES
JP2006538551A JP4839221B2 (en) 2003-11-07 2004-11-08 Combination therapy combination to increase HDL
CA002543596A CA2543596A1 (en) 2003-11-07 2004-11-08 Hdl-boosting combination therapy complexes
DE602004020649T DE602004020649D1 (en) 2003-11-07 2004-11-08 HDL REINFORCING COMBINATION THERAPY COMPLEXES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51809103P 2003-11-07 2003-11-07
US60/518,091 2003-11-07

Publications (2)

Publication Number Publication Date
WO2005046662A2 WO2005046662A2 (en) 2005-05-26
WO2005046662A3 true WO2005046662A3 (en) 2005-06-23

Family

ID=34590215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037324 WO2005046662A2 (en) 2003-11-07 2004-11-08 Hdl-boosting combination therapy complexes

Country Status (7)

Country Link
US (2) US7390504B2 (en)
EP (1) EP1680099B1 (en)
JP (2) JP4839221B2 (en)
AT (1) ATE428411T1 (en)
CA (1) CA2543596A1 (en)
DE (1) DE602004020649D1 (en)
WO (1) WO2005046662A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US20060134196A1 (en) * 2002-12-17 2006-06-22 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
JP4839221B2 (en) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Combination therapy combination to increase HDL
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
BRPI0513082A (en) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc fenofibrate formulations and related treatment methods
CA2576196A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
WO2007130714A1 (en) * 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20070185199A1 (en) * 2005-04-08 2007-08-09 Ju Tzuchi R Pharmaceutical formulations
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
JP2008546784A (en) 2005-06-20 2008-12-25 シェーリング コーポレイション Piperidine derivatives useful as histamine H3 antagonists
CN101500555A (en) * 2005-08-04 2009-08-05 变换药品公司 Novel formulations comprising fenofibrate and a statin, and related methods of treatment
US20080253985A1 (en) * 2005-10-18 2008-10-16 Wisler Gerald L Compositions for Lowering Serum Cholesterol and/or Triglycerides
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
PT2124884T (en) * 2006-12-22 2019-09-17 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
KR100877492B1 (en) 2007-04-27 2009-01-09 한국유나이티드제약 주식회사 Formulation of soft capsules for folic acid and the preparation thereof
WO2009033072A1 (en) * 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
EP2220208A4 (en) * 2007-11-23 2010-12-29 Rappaport Family Inst For Res Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
CA2728539A1 (en) * 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
US20100008956A1 (en) * 2008-07-08 2010-01-14 Jie Du Composition and combinations of carboxylic acid losartan in dosage forms
US20100317671A1 (en) * 2008-07-21 2010-12-16 Kaohsiung Medical University Xanthine-based cyclic gmp-enhancing rho-kinase inhibitor inhibits physiological activities of lung epithelial cell line
CN101836987B (en) * 2009-03-19 2013-03-27 西安万隆制药股份有限公司 Compound niacin sustained release tablet
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
US9481861B2 (en) 2011-07-12 2016-11-01 Foodchek Systems, Inc. Culture medium, method for culturing Salmonella and E. coli and method for detecting Salmonella and E. coli
CN103232398B (en) * 2012-04-28 2016-04-06 上海科州药物研发有限公司 A kind of Rosuvastatin amino acid salts and its preparation method and application
KR20170003611A (en) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Hdl therapy markers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) * 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (en) 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
JPS60136512A (en) 1983-12-26 1985-07-20 Eisai Co Ltd Remedy and preventive for hyperlipemia
DE3423166A1 (en) 1984-06-22 1986-01-02 Epis S.A., Zug ALPHA, OMEGA DICARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
AU1422388A (en) 1987-01-27 1988-08-10 Warner-Lambert Company Lipid regulating compositions
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
CA2039763A1 (en) 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
JP2999579B2 (en) 1990-07-18 2000-01-17 武田薬品工業株式会社 DNA and its uses
CA2048395A1 (en) 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (en) 1998-09-17 1999-09-06 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED.
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19858789A1 (en) 1998-12-18 2000-06-21 Bayer Ag Medicament combination of cerivastatin and fibrate, has additive effect in the treatment of lipid metabolism disorders, e.g. dyslipidemia or atherosclerosis
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2866400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
DE60037818D1 (en) 1999-04-01 2008-03-06 Esperion Therapeutics Inc ETHER COMPOUNDS, COMPOSITIONS AND ITS USE
US6631562B1 (en) 1999-10-13 2003-10-14 Ford Global Technologies, Llc Method for coating radiator support assembly
US6357821B1 (en) 1999-10-13 2002-03-19 Ford Global Technologies, Inc. Lamp can and radiator support assembly
US6502653B1 (en) 1999-10-13 2003-01-07 Ford Global Technologies, Inc. Multi-functional radiator support assembly
US6679545B1 (en) 1999-10-13 2004-01-20 Ford Global Technologies, Llc Multi-functional radiator support assembly
GR990100388A (en) 1999-11-09 2001-07-31 PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE....
MXPA02010316A (en) 2000-04-19 2005-04-19 Borody Thomas J Compositions and therapies for hyperlipidaemia associated disorders.
AU2001288294A1 (en) 2000-08-21 2002-03-04 Merck And Co., Inc. Anti-hypercholesterolemic drug combination
ATE424811T1 (en) 2000-08-31 2009-03-15 Jagotec Ag GROUND PARTICLES
JP2004508347A (en) 2000-09-06 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド Dihydroxy ring-opening salt of simvastatin
AU2001262945B2 (en) 2000-09-20 2006-02-02 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
NZ525921A (en) 2001-01-26 2005-06-24 Schering Corp Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1353695A2 (en) * 2001-01-26 2003-10-22 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
ATE369851T1 (en) 2001-01-26 2007-09-15 Schering Corp COMBINATIONS OF BALE ACID SEQUESTRANTS AND STEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS
US6534088B2 (en) 2001-02-22 2003-03-18 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
ES2259080T3 (en) 2001-04-30 2006-09-16 Pfizer Products Inc. PROCEDURES AND INTERMEDIATES TO PREPARE CETP INHIBITORS.
US7080486B2 (en) * 2001-07-12 2006-07-25 3M Innovative Properties Company Pass-through firestop device
AU2002332610B2 (en) * 2001-08-31 2007-11-08 Bristol-Myers Squibb Company Use of atazanavir in HIV therapy
US20060134196A1 (en) 2002-12-17 2006-06-22 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
JP4839221B2 (en) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Combination therapy combination to increase HDL

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
EP1680099B1 (en) 2009-04-15
ATE428411T1 (en) 2009-05-15
EP1680099A2 (en) 2006-07-19
US8258125B2 (en) 2012-09-04
US20080248070A1 (en) 2008-10-09
US20050101561A1 (en) 2005-05-12
DE602004020649D1 (en) 2009-05-28
US7390504B2 (en) 2008-06-24
JP2011153126A (en) 2011-08-11
WO2005046662A2 (en) 2005-05-26
CA2543596A1 (en) 2005-05-26
JP4839221B2 (en) 2011-12-21
JP2007509990A (en) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
AU2003279238A1 (en) Topical pharmaceutical composition comprising skin penetration enhancers for the treatment of warts
PT1509232E (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2004006858A3 (en) Compounds, compositions, and methods employing same
CA2504735A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103960A3 (en) Compounds and uses thereof
AU7031500A (en) Therapeutic quinazoline compounds
EP1638950A4 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1583534A4 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007079239A3 (en) Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2003080070A3 (en) Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
HK1082668A1 (en) Remedies for glomerular diseases
TNSN05306A1 (en) Substituted pyrrole derivatives.
MXPA03010761A (en) Pharmaceutical combinations.
EP1753425A4 (en) A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
MX2007006279A (en) Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors.
WO2005123068A3 (en) Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
AU2003285281A1 (en) Topical application of curcumin for the treatment of peripheral neuropathy
CA2540102A1 (en) A combination of candesartan and rosuvastatin for the treatment of atherosclerosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2543596

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006538551

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004810579

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004810579

Country of ref document: EP